Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164



Ciombor KK, Berlin J, Chan E.

Clin Cancer Res. 2013 Apr 15;19(8):1920-5. doi: 10.1158/1078-0432.CCR-12-2911. Epub 2013 Feb 26.


Aflibercept: A Review in Metastatic Colorectal Cancer.

Syed YY, McKeage K.

Drugs. 2015 Aug;75(12):1435-45. doi: 10.1007/s40265-015-0444-4. Review.


Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J.

Target Oncol. 2016 Jun;11(3):383-400. doi: 10.1007/s11523-015-0402-9.


A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.

Yoshino T, Yamazaki K, Yamaguchi K, Doi T, Boku N, Machida N, Onozawa Y, Asayama M, Fujino T, Ohtsu A.

Invest New Drugs. 2013 Aug;31(4):910-7. doi: 10.1007/s10637-012-9895-6. Epub 2012 Nov 20.


Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C.

J Clin Oncol. 2012 Oct 1;30(28):3499-506. Epub 2012 Sep 4.


Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

Ruff P, Ferry DR, Lakomỳ R, Prausová J, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Van Cutsem E.

Eur J Cancer. 2015 Jan;51(1):18-26. doi: 10.1016/j.ejca.2014.10.019. Epub 2014 Nov 14.


Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

Tabernero J, Van Cutsem E, Lakomý R, Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ.

Eur J Cancer. 2014 Jan;50(2):320-31. doi: 10.1016/j.ejca.2013.09.013. Epub 2013 Oct 16.


Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.

Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, Chistyakov V, Höhler T, Kim JS, Hofheinz RD, Ackland SP, Swinson D, Kopp M, Udovitsa D, Hall M, Iveson T, Vogel A, Zalcberg JR.

Ann Oncol. 2016 Jul;27(7):1273-9. doi: 10.1093/annonc/mdw176. Epub 2016 Apr 18.


Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.

Lambrechts D, Thienpont B, Thuillier V, Sagaert X, Moisse M, Peuteman G, Pericay C, Folprecht G, Zalcberg J, Zilocchi C, Margherini E, Chiron M, Van Cutsem E.

Br J Cancer. 2015 Sep 29;113(7):1027-34. doi: 10.1038/bjc.2015.329. Epub 2015 Sep 10.


[Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].

André T, Chibaudel B.

Bull Cancer. 2013 Oct;100(10):1023-5. doi: 10.1684/bdc.2013.1807. French.


Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.

Chung C, Pherwani N.

Am J Health Syst Pharm. 2013 Nov 1;70(21):1887-96. doi: 10.2146/ajhp130143. Review.


Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.

Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, Van Cutsem E.

Br J Cancer. 2013 Oct 1;109(7):1735-43. doi: 10.1038/bjc.2013.523. Epub 2013 Sep 17.


Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.

Salgado Fernández M, Pérez Hoyos MT, Díaz de Corcuera I, Vidal Arbués A, García de la Torre M.

Expert Opin Drug Saf. 2015 Aug;14(8):1171-9. doi: 10.1517/14740338.2015.1057495. Epub 2015 Jun 16.


Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.

Chong DQ, Manalo M, Imperial M, Teo P, Yong G, Ng M, Tan IB, Choo SP, Chua C.

Asia Pac J Clin Oncol. 2016 Sep;12(3):275-83. doi: 10.1111/ajco.12496. Epub 2016 Apr 14.


Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.

Saif MW.

Expert Opin Biol Ther. 2013 Nov;13(11):1489-93. doi: 10.1517/14712598.2013.837881. Epub 2013 Sep 19.


Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.

Lee JJ, Chu E.

Clin Colorectal Cancer. 2014 Sep;13(3):135-44. doi: 10.1016/j.clcc.2014.02.001. Epub 2014 Feb 27. Review.


Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF.

Clin Colorectal Cancer. 2013 Dec;12(4):239-47. doi: 10.1016/j.clcc.2013.09.001.


Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.

Feliu J, Díez de Corcuera I, Manzano JL, Valladares-Ayerbes M, Alcaide J, García García T, Vera R, Sastre J.

Clin Transl Oncol. 2017 Apr;19(4):498-507. doi: 10.1007/s12094-016-1556-3. Epub 2016 Oct 7.


Supplemental Content

Support Center